Drug Search Results
More Filters [+]

Hydroflumethiazide

Alternative Names: hydroflumethiazide, saluron, diucardin, salutensin-demi, salutensin
Latest Update: 2013-05-14
Latest Update Note: Clinical Trial Update

Product Description

Hydroflumethiazide is an intermediate-acting benzothiadiazine sulfonamide derivative belonging to the class of the thiazide diuretics. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Hydroflumethiazide)

Mechanisms of Action: NCCT Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Approved

Approved Countries: India | Ireland | Italy | New Zealand | Taiwan

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Hydroflumethiazide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

A6821003

N/A

Withdrawn

Hypertension

2015-02-01

Recent News Events

Date

Type

Title